See more : Litemax Electronics Inc. (4995.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of HOOKIPA Pharma Inc. (HOOK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HOOKIPA Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ibase Gaming Inc. (6441.TWO) Income Statement Analysis – Financial Results
- Companhia de Gás de São Paulo – COMGÁS (CGAS3.SA) Income Statement Analysis – Financial Results
- PT Super Energy Tbk (SURE.JK) Income Statement Analysis – Financial Results
- Headlam Group plc (HEAD.L) Income Statement Analysis – Financial Results
- Queen’s Gambit Growth Capital (GMBTW) Income Statement Analysis – Financial Results
HOOKIPA Pharma Inc. (HOOK)
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 20.13M | 14.25M | 18.45M | 19.58M | 11.94M | 7.63M | 0.00 |
| Cost of Revenue | 3.55M | 3.60M | 4.64M | 53.13M | 46.31M | 21.97M | 398.00K |
| Gross Profit | 16.58M | 10.65M | 13.81M | -33.55M | -34.37M | -14.34M | -398.00K |
| Gross Profit Ratio | 82.35% | 74.72% | 74.85% | -171.31% | -287.81% | -187.91% | 0.00% |
| Research & Development | 86.42M | 68.65M | 82.85M | 54.79M | 46.31M | 21.97M | 9.77M |
| General & Administrative | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Other Expenses | 0.00 | -392.00K | -2.84M | 3.07M | 601.00K | 133.00K | -25.00K |
| Operating Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Cost & Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Interest Income | 5.29M | 8.24M | 27.00K | 9.20M | 1.59M | 0.00 | 0.00 |
| Interest Expense | 317.00K | 687.00K | 898.00K | 786.00K | 877.00K | 778.00K | 606.00K |
| Depreciation & Amortization | 3.55M | 3.60M | 4.64M | 4.15M | 3.07M | 640.00K | 398.00K |
| EBITDA | -77.34M | -60.40M | -70.13M | -39.15M | -39.09M | -14.80M | -13.76M |
| EBITDA Ratio | -384.24% | -513.40% | -442.73% | -272.08% | -427.78% | -193.93% | 0.00% |
| Operating Income | -97.69M | -73.16M | -81.67M | -53.29M | -51.09M | -21.18M | -14.16M |
| Operating Income Ratio | -485.34% | -513.40% | -442.73% | -272.08% | -427.78% | -277.62% | 0.00% |
| Total Other Income/Expenses | 16.48M | 8.47M | 6.01M | 9.20M | 8.05M | 4.97M | 1.44M |
| Income Before Tax | -81.21M | -64.92M | -75.67M | -44.08M | -43.04M | -16.21M | -12.72M |
| Income Before Tax Ratio | -403.46% | -455.58% | -410.15% | -225.09% | -360.38% | -212.52% | 0.00% |
| Income Tax Expense | 368.00K | 230.00K | 1.00K | -10.28M | -8.89M | 24.00K | 4.00K |
| Net Income | -81.58M | -64.92M | -75.67M | -44.08M | -43.04M | -16.24M | -12.72M |
| Net Income Ratio | -405.29% | -455.58% | -410.15% | -225.09% | -360.38% | -212.83% | 0.00% |
| EPS | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| EPS Diluted | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| Weighted Avg Shares Out | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
| Weighted Avg Shares Out (Dil) | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
HOOKIPA Pharma Announces Board of Directors Changes
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know
Source: https://incomestatements.info
Category: Stock Reports